A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program ...

New leaders at GSK, Novo Nordisk and Sanofi are taking the reins at pivotal moments for three of pharma’s largest companies.

Dealmaking in the autoimmune space is thriving as biotechs chase new targets with the potential to treat more conditions.

Can Michael Halstead replicate the controlled growth he pulled off at Intra-Cellular Therapies in mental health’s psychedelic ...

Late-stage drugs in pancreatic cancer, multiple myeloma and Alzheimer’s could pair treatment advances with major commercial ...

What started as two neighbors trading shop talk has grown into Tyra Biosciences, a clinical-stage biotech company with a ...

Moderna notched a hard-fought FDA win earlier this month when the agency approved mFlusiva for adults aged 50 and older, ...

Less than a month after taking over as interim CEO of Legend Biotech, Alan Bash is signaling continuity rather than a reset. Bash joined Legend in October 2024 to lead its Carvykti business after two ...

Heidi Overton, a medical doctor and veteran of the America First think tank, currently serves as deputy director of the White ...

A personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower ...